Prognostic Implications of Antibodies to Soluble Liver Antigen in Autoimmune Hepatitis: A PRISMA-Compliant Meta-Analysis

Medicine (United States)

Volumn 94, Issue 23, 2015, Pages e953-

  Chen, Zhi Xian ^a   Shao, Jian Guo ^b   Shen, Yi ^b   Zhang, Jian ^b   Hua, Yu ^b   Wang, Lu Jun ^b   Qin, Gang ^b  

^a Nantong Health College of Jiangsu Province   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HLA DR3 ANTIGEN; LIVER ANTIGEN; SOLUBLE LIVER ANTIGEN; UNCLASSIFIED DRUG; AUTOANTIBODY; AUTOANTIGEN; LIVER ANTIGEN LA-1;

ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNE HEPATITIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FAILURE; LIVER TRANSPLANTATION; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; SYSTEMATIC REVIEW; BLOOD; IMMUNOLOGY;

AUTOANTIBODIES; AUTOANTIGENS; HEPATITIS, AUTOIMMUNE; HUMANS; PROGNOSIS;

EID: 84940033515     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000953     Document Type: Article

References (30)

1. Hurlburt KJ, McMahon BJ, Deubner H, et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97:2402-2407.
2. Gronbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2014;60:612-617.
3. Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol. 2008;43:1232-1240.
4. Kogan J, Safadi R, Ashur Y, et al. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol. 2002;35:75-81.
5. Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42:53-62.
6. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820-833.
7. Manns M, Gerken G, Kyriatsoulis A, et al. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. 1987;1:292-294.
8. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet. 2000;355:1510-1515.
9. Araiso Y, Palioura S, Ishitani R, et al. Structural insights into RNAdependent eukaryal and archaeal selenocysteine formation. Nucleic Acids Res. 2008;36:1187-1199.
10. Volkmann M, Luithle D, Zentgraf H, et al. SLA/LP/tRNP((Ser)Sec) antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract. J Autoimmun. 2010;34:59-65.
11. Ma Y, Bogdanos BP, Williams R, et al. Anti-SLA antibody is a marker of severity of liver damage in patients with autoimmune liver disease. J Hepatol. 2001;34:212.
12. Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity. 2002;35:475-483.
13. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51:259-264.
14. Zachou K, Gampeta S, Gatselis NK, et al. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. Liver Int. 2015;35:660-672.
15. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.
16. Zhang J, Shen Y, Cai H, et al. Hepatitis B virus infection status and risk of type 2 diabetes mellitus: a meta-analysis. Hepatol Res. 2015.
17. Kanzler S, Weidemann C, Gerken G, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol. 1999; 31: 635-640.
18. Efe C, Ozaslan E, Wahlin S, et al. Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study. Liver Int. 2013;33:190-196.
19. Montano-Loza AJ, Shums Z, Norman GL, et al. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int. 2012;32:85-92.
20. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:413-419.
21. Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol. 2000;33:208-215.
22. Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity. 2004;37:195-201.
23. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30:394-401.
24. Couto CA, Bittencourt PL, Porta G, et al. Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis. Hepatology. 2014;59:592-600.
25. Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology. 1997;25:317-323.
26. Czaja AJ, Carpenter HA, Santrach PJ, et al. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology. 1993;105:1502-1507.
27. Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Digest Dis Sci. 2000;45:1944-1948.
28. Werner M, Almer S, Prytz H, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol. 2009;50:388-393.
29. Danielsson Borssen A, Almer S, Prytz H, et al. Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis - a longterm follow-up study in 634 Swedish patients. Scand J Gastroenterol. 2015;50:217-223.
30. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med. 1996;101:422-434.